<DOC>
	<DOC>NCT02786576</DOC>
	<brief_summary>This study will assess the effects of adalimumab treatment in moderate to severe Hidradenitis Suppurativa (HS) patients in the real world setting. The objectives of this study are to estimate the effectiveness of adalimumab treatment on disease severity, to estimate the impact of adalimumab treatment on patients' quality of life, psychological effect, work productivity and healthcare resource utilization and to describe treatment practices over the study period.</brief_summary>
	<brief_title>Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Patients - a Multi cOuNtry studY in Real Life Setting</brief_title>
	<detailed_description />
	<mesh_term>Hidradenitis</mesh_term>
	<mesh_term>Hidradenitis Suppurativa</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Clinical diagnosis of moderate to severe Hidradenitis Suppurativa The decision to treat with adalimumab is made by the physician in accordance with the local label (Summary of Product Characteristics; product label) prior to any decision to approach the participant to participate in this study Participants willing to be involved in the study and to sign patient authorization form to use and disclose personal health information (or informed consent, where applicable) Participants in a clinical interventional study Participants treated with adalimumab prior to baseline visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Moderate to Severe Hidradenitis Suppurativa</keyword>
	<keyword>Adalimumab</keyword>
</DOC>